207 related articles for article (PubMed ID: 25711952)
1. The effect of C-reactive protein reduction with a highly specific antisense oligonucleotide on atrial fibrillation assessed using beat-to-beat pacemaker Holter follow-up.
Sugihara C; Freemantle N; Hughes SG; Furniss S; Sulke N
J Interv Card Electrophysiol; 2015 Jun; 43(1):91-8. PubMed ID: 25711952
[TBL] [Abstract][Full Text] [Related]
2. A double-blind, randomised, placebo-controlled, cross-over study assessing the use of XEN-D0103 in patients with paroxysmal atrial fibrillation and implanted pacemakers allowing continuous beat-to-beat monitoring of drug efficacy.
Shunmugam SR; Sugihara C; Freemantle N; Round P; Furniss S; Sulke N
J Interv Card Electrophysiol; 2018 Apr; 51(3):191-197. PubMed ID: 29460236
[TBL] [Abstract][Full Text] [Related]
3. Results of a proof of concept, double-blind, randomized trial of a second generation antisense oligonucleotide targeting high-sensitivity C-reactive protein (hs-CRP) in rheumatoid arthritis.
Warren MS; Hughes SG; Singleton W; Yamashita M; Genovese MC
Arthritis Res Ther; 2015 Mar; 17(1):80. PubMed ID: 25885521
[TBL] [Abstract][Full Text] [Related]
4. First clinical trial of specific IKACh blocker shows no reduction in atrial fibrillation burden in patients with paroxysmal atrial fibrillation: pacemaker assessment of BMS 914392 in patients with paroxysmal atrial fibrillation.
Podd SJ; Freemantle N; Furniss SS; Sulke N
Europace; 2016 Mar; 18(3):340-6. PubMed ID: 26462707
[TBL] [Abstract][Full Text] [Related]
5. A placebo-controlled, double-blind, randomized, multicenter study to assess the effects of dronedarone 400 mg twice daily for 12 weeks on atrial fibrillation burden in subjects with permanent pacemakers.
Ezekowitz MD; Ellenbogen KA; DiMarco JP; Kaszala K; Boddy A; Geba GP; Koren A
J Interv Card Electrophysiol; 2015 Mar; 42(2):69-76. PubMed ID: 25638303
[TBL] [Abstract][Full Text] [Related]
6. Are implantable cardiac monitors the 'gold standard' for atrial fibrillation detection? A prospective randomized trial comparing atrial fibrillation monitoring using implantable cardiac monitors and DDDRP permanent pacemakers in post atrial fibrillation ablation patients.
Podd SJ; Sugihara C; Furniss SS; Sulke N
Europace; 2016 Jul; 18(7):1000-5. PubMed ID: 26585596
[TBL] [Abstract][Full Text] [Related]
7. The effect of sinus rhythm restoration on high-sensitivity C-reactive protein levels and their association with long-term atrial fibrillation recurrence after electrical cardioversion.
Celebi OO; Celebi S; Canbay A; Ergun G; Aydogdu S; Diker E
Cardiology; 2011; 118(3):168-74. PubMed ID: 21654170
[TBL] [Abstract][Full Text] [Related]
8. New-generation atrial antitachycardia pacing (Reactive ATP) is associated with reduced risk of persistent or permanent atrial fibrillation in patients with bradycardia: Results from the MINERVA randomized multicenter international trial.
Padeletti L; Pürerfellner H; Mont L; Tukkie R; Manolis AS; Ricci R; Inama G; Serra P; Scheffer MG; Martins V; Warman EN; Vimercati M; Grammatico A; Boriani G;
Heart Rhythm; 2015 Aug; 12(8):1717-25. PubMed ID: 25869753
[TBL] [Abstract][Full Text] [Related]
9. Prognostic impact of hs-CRP and IL-6 in patients undergoing radiofrequency catheter ablation for atrial fibrillation.
Henningsen KM; Nilsson B; Bruunsgaard H; Chen X; Pedersen BK; Svendsen JH
Scand Cardiovasc J; 2009; 43(5):285-91. PubMed ID: 19117239
[TBL] [Abstract][Full Text] [Related]
10. The development of AF over time in patients with permanent pacemakers: objective assessment with pacemaker diagnostics demonstrates distinct patterns of AF.
Sugihara C; Veasey R; Freemantle N; Podd S; Furniss S; Sulke N
Europace; 2015 Jun; 17(6):864-70. PubMed ID: 26023175
[TBL] [Abstract][Full Text] [Related]
11. High-sensitivity C-reactive protein is predictive of successful cardioversion for atrial fibrillation and maintenance of sinus rhythm after conversion.
Watanabe E; Arakawa T; Uchiyama T; Kodama I; Hishida H
Int J Cardiol; 2006 Apr; 108(3):346-53. PubMed ID: 15964643
[TBL] [Abstract][Full Text] [Related]
12. Dronedarone for the control of ventricular rate in permanent atrial fibrillation: the Efficacy and safety of dRonedArone for the cOntrol of ventricular rate during atrial fibrillation (ERATO) study.
Davy JM; Herold M; Hoglund C; Timmermans A; Alings A; Radzik D; Van Kempen L;
Am Heart J; 2008 Sep; 156(3):527.e1-9. PubMed ID: 18760136
[TBL] [Abstract][Full Text] [Related]
13. Serum amyloid a and C-reactive protein independently predict the recurrences of atrial fibrillation after cardioversion in patients with preserved left ventricular function.
Barassi A; Pezzilli R; Morselli-Labate AM; Lombardi F; Belletti S; Dogliotti G; Corsi MM; Merlini G; Melzi d'Eril GV
Can J Cardiol; 2012; 28(5):537-41. PubMed ID: 22552174
[TBL] [Abstract][Full Text] [Related]
14. C-reactive protein elevation predicts the occurrence of atrial structural remodeling in patients with paroxysmal atrial fibrillation.
Watanabe T; Takeishi Y; Hirono O; Itoh M; Matsui M; Nakamura K; Tamada Y; Kubota I
Heart Vessels; 2005 Mar; 20(2):45-9. PubMed ID: 15772777
[TBL] [Abstract][Full Text] [Related]
15. Ferritin as a potential biomarker of efficacy of treatment of atrial fibrillation - preliminary report.
Sokal A; Wójcik S; Pruszkowska P; Kowalski O; Lenarczyk R; Liberska A; Mazurek M; Pluta S; Kalarus Z
Postepy Hig Med Dosw (Online); 2017 Oct; 71(0):876-880. PubMed ID: 29039347
[TBL] [Abstract][Full Text] [Related]
16. Predictors of atrial fibrillation recurrence after atrial fibrillation ablation with cryoballoon.
Evranos B; Aytemir K; Oto A; Okutucu S; Karakulak U; Şahiner L; Kaya B; Kabakçı G
Cardiol J; 2013; 20(3):294-303. PubMed ID: 23788304
[TBL] [Abstract][Full Text] [Related]
17. Relationship between inflammatory markers and clinical patterns of atrial fibrillation in patients with congestive heart failure.
Targoński R; Salczyńska D; Sadowski J; Cichowski L
Kardiol Pol; 2008 Jul; 66(7):729-36; discussion 737-9. PubMed ID: 18690564
[TBL] [Abstract][Full Text] [Related]
18. Natriuretic Propeptides as Markers of Atrial Fibrillation Burden and Recurrence (from the AMIO-CAT Trial).
Darkner S; Goetze JP; Chen X; Henningsen K; Pehrson S; Svendsen JH
Am J Cardiol; 2017 Oct; 120(8):1309-1315. PubMed ID: 28865890
[TBL] [Abstract][Full Text] [Related]
19. Phased multipolar radiofrequency pulmonary vein isolation is as effective and safe as conventional irrigated point-to-point ablation. A prospective randomised 1-year implantable cardiac monitoring device follow-up trial.
Podd SJ; Sulke AN; Sugihara C; Furniss SS
J Interv Card Electrophysiol; 2015 Dec; 44(3):257-64. PubMed ID: 26310300
[TBL] [Abstract][Full Text] [Related]
20. Fast atrial activity predicts recurrence of atrial fibrillation after pulmonary vein isolation: results from a prospective randomized study.
Kriatselis C; Kaufmann J; Nedios S; Liu J; Gerds-Li JH; Fleck E
J Interv Card Electrophysiol; 2015 Mar; 42(2):101-6. PubMed ID: 25591723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
